Trials / Completed
CompletedNCT00424710
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy (PEARL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Hawaii Pacific Health · Academic / Other
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
Detailed description
Previous treatment in subjects is allowed as long as appropriate washout period has elapsed. Patients will be followed by 4M ETDRS vision testing as well as scheduled OCT, ICG, FA and Fundus Photography.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab intravitreal injection | liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2007-01-19
- Last updated
- 2014-11-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00424710. Inclusion in this directory is not an endorsement.